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There is strong interest in developing practical strategies for gene delivery to the central nervous system (CNS). Direct delivery into the
brain or spinal cord is highly invasive as well as inefficient or hazardous using most current vector systems. Our objective was to generate
innocuous gene vehicles that would be effectively taken up by axons and then home to the neuron cell bodies. Vectors derived from Adeno-
Associated Virus (AAV), a harmless human parvovirus, offer strong starting candidates for deriving such vehicles. Enhancing the axonal
uptake of AAV, and conferring more efficient retrograde transport capabilities upon the virus, should produce near ideal gene transfer vehicles
for the CNS. To enhance retrograde transport of the virus, peptides mimicking binding domains for cytoplasmic dynein were inserted in the
capsid by directed mutagenesis. In separate clones, peptides derived from an NMDA receptor antagonist were also introduced to provide a
specific affinity for this receptor. When combined, these two functionally distinct classes of mutation enabled efficient gene transfer into
neurons under conditions not permissive for standard AAV-2 vectors prepared under the same conditions. These results hold strong promise
for the development of safe, convenient vehicles to target genes and other sequences to neurons, enabling new and novel approaches for the
treatment of multiple neurological disorders.
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There is keen interest in developing practical strategies
for gene delivery into the central nervous system (CNS). In
addition to many obvious applications for basic research, the
ability to safely and efficiently engineer genes and other
sequences into CNS cell populations will generate major
new therapeutic possibilities for chronic as well as acute
neurological disorders. Unfortunately, the distinctive fea-
tures of neurons, and their complex interconnections impose
stringent requirements upon gene delivery systems, render-
ing most current viral and other types of vectors poorly
suited for this purpose. For example, gene vectors do not
penetrate the tegument surrounding the spinal cord, and
direct injection into the cord tends to produce spots of
localized intense gene transfer, with minimal lateral0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.051
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infuse vectors through the cerebrospinal fluid (CSF) with
some success (Cunningham et al., 2000). However, the
present state of affairs remains far from ideal, particularly
where the goal is to engineer new sequences into motor or
sensory neurons, and less invasive strategies are highly
desirable. A convenient, minimally invasive approach
would enable a vector to be delivered by simple intra-
muscular (IM) or intravenous (IV) injection, after which the
virus would home to and be absorbed by targeted axons and
transported back to the neuronal cell bodies. Such, after all,
are the natural routes of infection of several pathogenic
neurotropic viruses, upon reaching the blood or epithelial
linings (Leopold et al., 2000; Jacob et al., 2000). HSV
derivatives as well as lentiviral vectors pseudotyped with
rabies envelope glycoprotein can travel efficiently along
neuronal axons, but bring their own particular limitations
and issues (Mikkers and Berns, 2003; Fortunato and
Spector, 2003; Pakzaban et al., 1994).05) 203 – 214
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derived from Adeno-Associated Virus (rAAV) offer a
strong set of starting candidates for applications in the
CNS. Derived from a family of small non-pathogenic
human parvoviruses, AAV vectors are capable of effi-
ciently delivering gene cassettes of up to about 5 kb.
Recombinant AAV (rAAV) carry no viral coding sequen-
ces, so no viral products are synthesized in the target cells.
Unlike complex lentiviruses and simpler murine retrovi-
ruses, integration is not a prerequisite for transcription of
AAV gene cassettes. Integration by standard AAV vectors,
as opposed to wild type (wt) AAV, is slow, inefficient, and
non-specific, and the majority of transgenes persist as
highly stable, actively transcribed episomes, minimizing
concerns about insertional mutagenesis. As a consequence,
recombinant AAV are poorly suited for long-term gene
transfer into rapidly dividing cells, but will readily persist
for months to years in slowly dividing or non-dividing
lineages. A further advantage is the low immunogenicity
of the AAV capsid compared with other viral vectors such
as Adenovirus (Bessis et al., 2004). Although some
variability has been reported with strain of animal and
site of delivery, exposure to rAAV, particularly a single
administration, does not typically elicit destructive cellular
immune responses against transduced cells in immuno-
competent animals.
Although AAV is a human virus, AAV vectors function
equally effectively in cells of many other species, including
rodents, dogs, and other primates, streamlining transitions
from animal model systems to clinical trials. All these
features have served to make rAAV increasingly popular as
research tools and for gene therapy applications, as rAAV
gain increasing acceptance for use in human trials (Kay et al.,
2000; Athanasopoulos et al., 2000; Mandel and Burger,
2004).
The natural cellular tropism of AAV is broad, and
standard AAV vectors have been used to transduce a broad
spectrum of cell types, especially in vitro, including
neurons. Unfortunately for applications in the CNS, stand-
ard vectors derived from AAV-2, the most commonly used
and best characterized serotype, do not disperse widely after
injection in the brain and do not reach neuron cell bodies
very efficiently following injection into peripheral sites. For
example, after IM injection, rAAV are principally absorbed
by myocytes. At least two studies failed to detect the vector
in spinal cord neurons following IM injections of rAAV-2
(Martinov et al., 2002, Wang et al., 2002). Deficient
retrograde transport in brain neurons has also been reported
(Chamberlin et al., 1998). Recently, Kaspar et al. (2003)
demonstrated retrograde transport of an AAV-2 IGF-1 vector
to motor neurons after injection in SODG93A mice, suf-
ficient for biological effects of the treatment to be apparent,
but still at low levels that served to emphasize the overall
inefficiency of the process.
Two distinct properties crucial to viruses targeting
neurons appear lacking in AAV-2, a specific means ofentry, and an efficient mechanism for keying into a
retrograde transport pathway. Despite the susceptibility of
neurons to the virus, AAV-2 may not be absorbed well by
neuronal axons and dendrites. Examples of viruses which
exhibit efficient uptake and retrograde transport along
neural axons include the rabies viruses, herpes viruses,
and even certain pathogenic parvoviruses. In some instan-
ces, particular features of their capsids which confer these
traits have been identified, enabling attempts at re-engineer-
ing such properties into more innocuous vectors such as
AAV. This is assisted by the availability of detailed X-ray
crystallographic structures, particularly for AAV-2 (Xie et
al., 2002), as well as the identification of domains in the
major capsid protein (VP3) which will tolerate short peptide
inserts (Shi et al., 2001; Wu et al., 2000; Grifman et al.,
2001; Nicklin et al., 2001). This is the approach we adopted
to enhance the neurotropism of rAAV-2.Results
Mutagenesis of the AAV capsid
As distinct attributes, it is problematic to imagine a single
small peptide insert conferring neuron-specific uptake as
well as efficient retrograde transport. However, new func-
tional epitopes need not be reiterated in every capsid
component for powerful effects to be achieved. Each AAV
capsid is assembled from about 60 building blocks of the
major capsid protein VP3, as well as lesser amounts of other
subunits produced by alternative splicing of the cap mRNA.
A mix of capsid gene plasmids incorporating different
changes will, when transfected together into packaging
cells, therefore result on average in many copies of each
mutation being expressed on the surface of most virus
particles.
Our strategy for modifying the AAV-2 capsid was two-
tiered. Initially, we incorporated peptides derived from the
sequence of histogranin (HN) (Lemaire et al., 1993, 1995).
A short 15-amino acid peptide, HN is a potent NMDA
receptor antagonist, and efficiently displaces NMDA recep-
tor ligand binding (Lemaire et al., 1993; Shukla et al.,
1995). The specificity of HN for NMDA receptors is
demonstrated by its ability to protect against NMDA-
induced convulsion, but not convulsion induced by other
ionotropic glutamate receptor agonists such as AMPA or
kainate (Lemaire et al., 1995). NMDA receptors are
expressed across wide swaths of the CNS, and can be
found at high levels on axons as well as cell bodies on
pyramidal neurons in the brain (Conti, 1997; Moriyoshi et
al., 1991), on ventral horn motor neurons (O’Donnell et al.,
2004), and on dorsal ganglion sensory neurons (Ma and
Hargreaves, 2000), among others. Peptides mimicking
either the natural HN sequence, [Met1]HN, or an analog,
[Ser1]HN, with a single amino acid substitution that results
in a somewhat higher binding affinity and increased stability
Fig. 1. Changes introduced in the AAV-2 capsid. Illustration of mutations
introduced in the VP3 sequence in separate clones of plasmid pXX2,
encoding the AAV-2 rep and cap functions.
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in position 587 in VP3. This domain in loop IV is
recognized as a tolerant site in the capsid, involved in the
interaction of AAV-2 with Heparin Sulfate Proteoglycan
(HSPG) in the normal binding of the virus to the host cell
(Girod et al., 1999; Grifman et al., 2001; Shi et al., 2001;
Ried et al., 2002). Small disruptions in this domain can
result in reduced HSPG binding, but need not interfere with
virus assembly.
In a second phase, to achieve more efficient retrograde
transport, we attempted to confer on the capsid a specific
affinity for cytoplasmic dynein. Many cellular proteins as
well as neurotropic viruses (Mueller et al., 2002; Topp et al.,
1994) rely upon cytoplasmic dynein, one of two major types
of Dynein Motor Complex (DMC), for retrograde transport
(Schnapp and Reese, 1989). Cytoplasmic dynein is a large
protein complex composed of multiple subunits, with the
heavy chains containing the motor domains, while inter-
mediate and light chains serve to bind the complex to
different cargo proteins (Susalka and Pfister, 2000; Pazour et
al., 1998). Recent studies have identified specific compo-
nents of several light chains which are in direct association
with different cargo proteins (Jacob et al., 2000; Rodriguez-
Crespo et al., 2001; Mueller et al., 2002). For example, using
a pepscan technique, Rodriguez-Crespo et al. (2001)
identified two consensus motifs, GIQVD and KSTQT, across
a panel of 10 cargo proteins all interacting with an 8-kDa
light-chain component (LC8). In particular, the KSTQT
motif was common to proteins found in several neurotropic
viruses, including Mokola virus, rabies virus, and African
swine virus (Rodriguez-Crespo et al., 2001). In a different
study, an SKCSRmotif within the poliovirus receptor CD155
was shown to interact with a different dynein light chain,
Tctex-1 (Mueller et al., 2002). None of these motifs are
normally displayed on the AAV capsid. To enhance retro-
grade transport, sequences encoding peptides derived from
several of these motifs were inserted into separate clones of
VP3, again centered at position 587, to yield clones AAV-
DMC1 (KSTQT), AAV-DMC2 (SKCSR), and AAV-DMC3
(GIQVD).
In addition to the disruption of the native sequence at this
site, a specific deletion was introduced in most of the
mutants, encompassing residues 584–589, including two
arginines at 585 and 588. Two recent mutagenesis studies
implicated these residues in the efficient interaction of the
capsid with HSPG, although other sites were also important
(Opie et al., 2003; Kern et al., 2003). See Fig. 1 andMaterials
and methods for additional details of the constructs and
mutagenesis.
Next, vector preparations were generated in which a lacZ
cassette was packaged in either class of mutant capsid alone,
or in a 1:1 mix of an HN insert together with a DMC
binding peptide, or in the standard AAV-2 capsid as a
control. All mutants packaged with near-normal efficiencies,
with typical genomic titers insignificantly different from the
wild type. Viruses were purified by passage over iodixanolgradients followed by ion exchange chromatography, a
methodology not dependent on the affinity of the virus for
heparin. Elution over 1-ml heparin columns revealed modest
(less than 1 log) differences between mutants and standard
AAV-2 in heparin binding affinity (not shown).
Gene transfer into PC-12 cells by capsids with engineered
peptide motifs
The properties of rAAV bearing these different peptides,
alone or in combination, were contrasted against those of the
standard AAV-2 vector in differentiated PC-12 cells, a rat
pheochromocytoma line retaining many characteristic neuro-
nal properties, including expression of NMDA receptors
(Casado et al., 1996). In differentiated PC-12s, expression of
the transgene following exposure to the standard rAAV-2
lacZ was poor (1–3%) to negligible, consistent with previous
experiences of our group and others. Modest but reproducible
improvements in efficiency were seen with vectors bearing
either the KSTQT motif (DMC1) or an HN peptide insert
alone. Exposure to these vectors resulted in up to several fold
more lacZ expressing cells than the standard AAV-2, with up
to 10–15% of the cells expressing beta-galactosidase (beta-
gal) at an MOI of about 100. However, after exposure to an
equivalent dose of a double mutant vector bearing both the
DMC1 and HN1 motifs, the numbers of lacZ expressing cells
were at least 6- to 8-fold higher compared with vectors
displaying either motif alone, with greater differences evident
at lower input doses. Representative results are shown in Fig.
2. Comparisons between the 2 variants of the HN motif in
PC-12s did not reveal significant phenotypic differences.
Capsids bearing the DMC2 or DMC3 motifs did not display
phenotypes clearly distinctive from AAV-2 in initial trials,
and were not characterized further.
To confirm that the enhanced gene expression by the
double mutant was mediated at least in part via NMDA
receptors, the transduction was competed with excess HN
peptide (Bachem, Torrence, CA). Pre-incubation with the HN
reduced the transduction efficiency of AAV-HN1/DMC1 in
PC-12s back to low levels (see Fig. 3A). Selected cultures
Fig. 2. Transduction of differentiated PC-12s with mutant AAV-2 vectors. After treatment with NGF for 7 days, differentiated PC-12s reached a final density of
approximately 106 cells/well. The cells were then either mock transduced (A) or received 10 Al of either standard rAAV-lacZ (B) or an engineered vector with
the indicated capsid insert (C–E). The cells were fixed and stained with X-gal 48 h later.
Fig. 3. Inhibition of NMDA-R-dependent vector uptake and DMC-depend-
ent transport in PC-12 cells. (A) PC-12s were pre-incubated with 20 AM
histogranin peptide for 15 min before addition of 10 Al of the AAV-HN1/
DMC1 chimera carrying a lacZ transgene (right panel). Control cultures
received AAV with no peptide (left panel). The medium was changed after
18 h and the cells fixed and stained with X-gal 2 days later as described in
Fig. 2. (B) PC-12s were pretreated with 20 AM sodium orthovanadate
(Na3VO4) for 2 h prior to addition of AAV-HN1/DMC1 (right panel).
Control cultures received AAV with no vanadate (left panel). The medium
was changed 14 h later and the cells were fixed and stained as in panel A.
J. Xu et al. / Virology 341 (2005) 203–214206were also pretreated with sodium vanadate, a potent inhibitor
of the dynein motor complex. This treatment also suppressed
gene transfer by the double mutant, as shown in Fig. 3B. A
similar effect of vanadate upon gene transfer by standard
rAAV-2 in susceptible cell lines such as 293 was not observed
(not shown).
Gene transfer into dorsal root ganglia neurons
The AAV-DMC1 and AAV-HN1 viruses, as well as the
chimeric combination, were next evaluated in cultures of
sensory neurons isolated from neonatal rat dorsal root
ganglia (DRG). Gene transfer by standard rAAV-2 in
dissociated DRG was very poor, resulting in only a few
percent of the cells expressing beta-gal after exposure at
high MOI. A vector bearing both the HN1 and DMC1
motifs transduced with much higher efficiency, with at least
50% of the cells expressing the transgene at a similar input
dose. Vectors bearing single mutations yielded intermediate
efficiencies, similar to the findings in PC-12s (see Fig. 4).
To demonstrate the specific contribution of the KSTQT
motif in AAV-DMC1 in enhancing retrograde transport, the
viruses were next applied selectively to the axons of the
dorsal root ganglia, by culturing the cells in the Campenot
format (Campenot, 1977, 1994). In these cultures, the cells
are added to a central well partitioned with watertight barriers
from separate chambers on either side. The neuron cell bodies
remain isolated in the center well, but their axons and
associated glia extend through the junctions into the side
chambers due to a gradient of nerve growth factor (NGF). In
this way, axons and neuron cell bodies become sequestered in
separate fluid environments (see Fig. 5A). The Campenot
format serves as a stringent in vitro test for both efficient axon
Fig. 4. Gene transfer into dissociated dorsal root ganglia cultures using mutant AAV vectors. 2  105 neurons/well were plated initially, and cultured for 7 days.
The cells were then either mock transduced (A) or received 10 Al of the standard rAAV-lacZ (B) or one of the modified lacZ vectors (C–E), as indicated. The
cells were fixed and stained 48 h after transduction.
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prevent successful gene transfer into the neurons.
Eight days after establishment, addition of the standard
AAV-lacZ to selected side chambers failed to produce any
lacZ expression in the central wells, in repeated trials.
Exposure of axons to AAV capsids bearing either the
KSTQT or HN motifs alone also produced either no or
very few (2–4) beta-gal expressing cells in the corre-
sponding central wells, although many cells in the treated
side chambers expressed beta-gal, particularly after expo-
sure to AAV-DMC1. Only after chimeric AAV-HN1/
DMC1 capsids were added to side chambers did signifi-
cant numbers of central well cell bodies express beta-gal
(about 350 in one trial) (see Fig. 5B). No clustering of
beta-gal positive neurons near the boundary with the
treated side chamber was seen. Short pretreatment of the
side chambers with HN peptide prior to addition of the
AAV-HN1/DMC1 effectively blocked lacZ expression in
the central wells (see Fig. 5C). Limited trials conducted
with a different indicator, Red Fluorescent Protein (RFP),
produced similar patterns.
That the expression pattern of the chimeric AAV-HN1/
DMC1 vector in the Campenot cultures correlated with
many more copies of its transgene reaching the central wells
was confirmed by real-time PCR. Heightened levels (1–2
logs) of transgene DNAwere detected in central chambers 2
days after addition of the chimera to the axon chambers,
compared with exposure to standard AAV-2 — 44.8  103
copies versus 1.36  103, respectively, in one trial. No virus
signal was detected in culture medium from any of the
central wells, or from side chambers not exposed to an
rAAV, verifying the integrity of the watertight seals between
the chambers, and confirming the appearance of the trans-
gene and its protein product in neurons was not due to
leakage of virus across the seals.Binding of mutant AAV capsids to cytoplasmic dynein
To verify the phenotypic changes in retrograde transport
and transduction efficiency produced by the DMC1 peptide
insert correlated with a new binding affinity of these capsids
for a specific component of cytoplasmic dynein, plasmids
encoding either the standard AAV-2 rep and cap gene
sequences or the mutant bearing the DMC1motif in cap were
transfected into 293 cells. Cell lysates were prepared 24 h
later and immunoprecipitated under non-reducing conditions
with an antibody against the AAV capsid protein. The
immunoprecipitation products were then run on gels and
visualized using a specific antiserum against LC8, the
cytoplasmic dynein light chain to which the KSTQT motif
in DMC1 was designed to bind. As shown in Fig. 6,
immunoprecipitation of the standard capsid did not co-
immunoprecipitate LC8, as expected. But immunoprecipita-
tion of the AAV-DMC1 capsid also brought down LC8,
confirming binding of the mutant to this DMC polypeptide.
Gene transfer into other cell types using mutant AAV
capsids
As noted in Campenot experiments, direct exposure to
rAAV bearing the DMC1 motif produced more extensive
transgene expression in side chamber cells exposed to these
vectors than exposure to standard rAAV-2. More glial cells
were transduced using either AAV-DMC1 or AAV-HN1/
DMC1, compared with the standard rAAV-2 or AAV-HN1
vectors. The phenotypes of these capsids were compared next
across a panel of non-neuronal cell lines, including 293,
HeLa, CEM (a human T cell line), and DITNC (an
immortalized rat astrocyte cell line). No enhancing effect of
the HN peptide insert was observed in these cell types, in
keeping with its specific affinity for NMDA receptors. In
Fig. 5. Enhanced gene transfer into Campenot cultures of dorsal root ganglia neurons by mutant AAV vectors. (A) Diagram of Campenot format. Two side
chambers separated from a central well were established using Teflon dividers attached with grease to a 35-mm dish. 105 neurons were plated initially in each
central chamber. Guided by an NGF gradient between the central and side chambers, axons extend into the side chambers along parallel scratches etched in the
plastic. Cell survival after 8 days was estimated at 50%. (B) AAV-mediated gene transfer into Campenot cultures. Eight days after establishment of the cultures
in panel A, 10 Al of each vector was added to one side chamber of each culture. The other side chamber was left untreated. 48 h later, the central and side
chambers were fixed and stained for beta-gal expression. Horizontal lines visible across the central chambers are grooves etched in the plastic as a guide for
neurite outgrowth. (C) Histogranin inhibition of gene transfer mediated by a chimeric AAV vector. Histogranin peptide was added to one axon chamber of
different Campenot cultures at a final concentration of either 20 or 50 AM, 10 min prior to addition of 10 Al of AAVHN1/DMC1. After 18 h, the medium was
changed in this chamber and the culture was maintained for an extra 30 h before fixing and staining as described in panel B.
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DMC-1 was reproducibly higher in some lines than after
exposure to standard AAV-2, particularly at lower input MOI.
Differences were marginal in CEMs, but more notable inothers, ranging from less than 2- to more than 5-fold. Results
from several trials are shown in Fig. 7.
Retrograde transport mediated by cytoplasmic dynein is
not only active in neurons. To look more closely at this effect
Fig. 6. Co-immunoprecipitation of LC8 light chain with an AAV capsid
antibody. 293 cells were transfected with either the standard pXX2 or
mutant pXX2-DMC1 plasmids. Untransfected cells served as a negative
control. 24 h later, clarified cell lysates were prepared under non-denaturing
conditions and immunoprecipitated with an AAV capsid antibody (A20).
The precipitated immune complexes (lanes 2 to 5) as well as their
respective supernatants (lanes 5 to 9) were resolved by SDS-PAGE and
immunoblotted with anti-LC8 antibody. Lane 1, input control lysate; lane 2,
IP of control lysate; lane 3, IP of lysate from cells transfected with pXX2;
lane 4, IP of lysate from cells transfected with pXX2-DMC1; lane 5, same
as lane 4 except the anti-AAV antibody was omitted; lanes 6 to 9,
supernatant from IPs corresponding to lanes 2 to 5, respectively; lane 10,
protein G-agarose alone.
Fig. 8. Transduction of 3T3 cells by standard rAAV-2 or AAV-DMC1. 3T3
cells were incubated in the presence or absence of 10 mM HU for 2 h prior
to rinsing with PBS and replenishment with new medium. The HU-treated,
as well as the untreated control cells, were then transduced with 10 Al of
either the standard AAV-2 or AAV-DMC1 lacZ vectors. The cells were
fixed and stained with X-gal 48 h after transduction.
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cells, AAV-DMC1 was tested on a cell type strongly resistant
to standard AAV-2, murine 3T3 cells. Unlike cells that simply
lack viral receptors, 3T3s are not impaired for binding or
entry of AAV-2, yet still transduce very poorly. After
internalization, AAV virions are localized initially in early
endosomes from which they cannot escape. In 3T3s, further
maturation of these endosomes is impeded, compared with
more easily transduced cell types such as 293 (Hansen et al.,
2000; Hansen et al., 2001). This block to transduction can be
overcome by pretreatment of 3T3s with agents such as
hydroxyurea (HU) which promote endosome acidification.
Following HU treatment of 3T3s, AAV particles can be found
in late endosomes and lysosomes from which escape is
unimpaired. Because the rate-limiting step is a block in
intracellular trafficking, and the insert in the DMC1 capsid
appeared to affect transport of the virus, the susceptibility of
3T3s to gene transfer mediated by this virus was compared
against standard AAV in the presence or absence of HU. As
shown in Fig. 8, the standard AAV-2 lacZ vector transducedFig. 7. Transduction of non-neuronal cells with standard rAAV-2 or AAV-DMC1.
two vectors, and fixed and stained with X-gal 48 h later. An MOI of about 50 wthe cells at only a very low level, as expected. Pretreatment
with HU increased the number of cells expressing beta-gal
several fold. However, the percentage of cells expressing the
transgene after delivery in the DMC1 capsid was much
higher, even without HU, and the transduction was not
enhanced further by HU treatment.
Injection of standard rAAV-2 and a chimeric capsid in a
mouse tongue model
As an initial test of efficacy in vivo, either the AAV-HN1/
DMC1 mutant or regular rAAV-2 were applied to a standard
animal model for retrograde transport. Ten microliters of
each vector was injected into the tongues of two groups of
mice. Selected animals were then sacrificed at several timeHeLa cells, rat astrocytes, or CEM cells were transduced with either of the
as used for the cell lines except CEM, where the MOI was 100.
Table 1
AAV copy numbers in brain stems of tongue-injected mice
Vectorsa Brain stemb Tonguec
24 h 48 h 72 h 24 h 48 h 72 h
AAV-2 0 0 0 98,492 4306 2435
AAV-HN1/DMC1 0 490 2771 146,944 18,078 677
Values reflect transgene copy numbers per tissue block. All values were
subtracted from the mean of the negative control samples. Values less than
1 SD from the mean of the negative controls were regarded as insignificant.
a 10 Al of the indicated vector was injected into the front half of each
tongue.
b 20 mg of brain stem tissue including both hypoglossal nuclei from each
mouse was dissected for DNA extraction at the indicated times.
c 20-mg samples were also collected from each tongue near the injection
site.
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and DNAwas extracted for real-time PCR. Samples of brain
and tongue tissue from control mice were also collected as
negative controls. As expected, large quantities of vector
DNA were present in tongues of animals receiving either
vector, particularly immediately after injection. No signal
above baseline was detected in brain stems of animals
receiving only standard rAAV-2 at any time point. Follow-
ing injection of AAV-HN1/DMC1, no signal was present
after 24 h, but brain stems collected after 48 or 72 h were
found to harbor up to several thousand copies of the vector
transgene (see Table 1).Discussion
Successful attempts to alter the tropism of AAV have
typically taken the form of small discrete changes in the
major cap gene sequence intended to confer a single new
property. In this study, two distinct types of capsid mutation
were introduced in separate VP3 clones, and then combined
to yield chimeric virions exhibiting enhanced gene transfer
capabilities in NMDA-R expressing neurons. This new
tropism was achieved not by mixing two motifs intended to
influence the same property, but rather by peptide inserts
designed to affect distinctly different characteristics of the
capsid. The full impact of the phenotypic changes was only
apparent in the context of neurons, and was most evident
in instances where successful transduction was heavily
dependent upon axonal uptake as well as efficient retrograde
transport of the particles.
Synergistic effects of the mutations were seen in differ-
entiated PC-12 cells and in cultures of dorsal root ganglia
neurons. The PC-12s and DRG were only poorly susceptible
to standard rAAV-2-mediated gene transfer, and in the
Campenot format the latter also offered a rigorous test of
each vector’s capacity for retrograde transport. The results
in the Campenot cultures also provide insight into the
constraints upon standard rAAV-2-mediated gene transfer in
neurons. In theory, the lack of transgene expression in the
neuron cell bodies following axonal exposure to standardrAAV-2 could result from limited binding or uptake of the
virus by the axons, inefficient retrograde transport, or both.
Comparing the performance of the different mutant capsids
against that of the standard rAAV-2 indicates both are
important contributors to the poor performance of the
standard vector in this context. Providing a new affinity
for a specific receptor on the axons, via the HN motif, did
not in and of itself notably enhance transduction of the
neurons. Conversely, when the vector was altered to home
to an efficient retrograde transport pathway, minimal
neuronal transgene expression occurred in the absence of
the other peptide conferring affinity for NMDA-R.
The enhanced expression conferred by the DMC1 motif
alone in some other cell types is also interesting, since this
peptide insert is not designed to affect entry of the virus.
AAV trafficking to the perinuclear region subsequent to
endocytosis is mediated via endosomes, from which the
virus then escapes to localize in the nucleus where
uncoating and second-strand DNA synthesis occur. In 3T3
cells, where normal maturation of these endosomes is
impaired, the effect of the DMC1 motif was dramatic, and
essential for vigorous transduction. Details regarding the
intracellular transport of AAV-DMC1 remain to be deter-
mined; the trafficking even of standard AAV remains an
active area of investigation. But these observations are in
line with its conferred ability to bind the LC8 light chain of
cytoplasmic dynein, and consistent with the peptide insert in
this capsid directly affecting trafficking of the virus.
This capability of the DMC1 motif suggests that this type
of mutation could be valuable for other gene therapy
applications unrelated to the central nervous system. There
have been recurring difficulties in practice with many
strategies designed to target AAV as well as other vectors
to heterologous receptors. In some cases, this was due to an
innate attribute of the targeted receptor, such as very slow
uptake of ligand–receptor complexes. However, when a
viral vector is redirected to a foreign receptor, some or most
of the particles may traverse the intracellular pathway
normally taken by its receptor–ligand complexes after
uptake, which may be incompatible with expression of the
genetic payload of the vector. This has been a problem with
attempts to re-target viruses to, for example, the EGF
receptor (Cosset et al., 1995; Erlwein et al., 2002). By virtue
of its ability to override some non-productive pathways, as
in 3T3 cells, and redirect the virus to the DMC, motifs such
as DMC1 could be beneficial to other targeting strategies.
In summary, the HN and DMC1 mutations, and their
combination, represent a highly promising set of engineered
gene vectors. The ability to deliver therapeutic sequences in
vehicles specifically tailored to CNS populations would
enable new and novel approaches to treating an array of
serious debilitating neurological disorders, providing strong
motivation for further research in this direction. Additional
characterization of such chimeras will in turn lead to further
refinements to optimize performance. For example, the
chimeric virions are not a pure population. Individual
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different ratios. It is possible a specific capsid ratio
contributes disproportionately to the novel phenotype
observed with the population as a whole. Gigout et al.
recently reported that mosaic virions containing a mix of a
capsid mutant together with the wild-type capsid protein had
properties distinct from pure virions of either type alone
(Gigout et al., 2005).
These findings also further expand the possibilities
available for generating novel chimeric AAV. With clones
from a rapidly increasing number of distinct AAV
becoming available, derived from human as well as
non-human sources (Mori et al., 2004), investigators have
already begun to explore the properties of chimeric
capsids containing components of more than one type
of AAV (Hauck et al., 2003; Rabinowitz et al., 2004) or
even recombinant capsid proteins bearing epitopes from
more than one strain (Bowles et al., 2003). The ability to
mingle different mutant capsids together to generate
viruses with unique functionalities further expands the
pool of AAV chimeras available for research and therapy.
This remarkable plasticity of the vector system should
greatly increase the pace with which valuable derivatives
of AAV with properties tailored for specific applications
are identified.Materials and methods
Primary cells and cell lines
293 cells, an adenovirus-transformed human embryonic
kidney cell line, were maintained in Eagle’s minimal
essential medium (Mediatech Cellgro, Herndon, VA, USA)
containing 10% fetal bovine serum (FBS) (Gibco BRL
Life Technologies, Grand Island, NY, USA) and 100 U/ml
penicillin–100 Ag/ml streptomycin (pen-strep). HeLa,
DITNC, and NIH 3T3 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco BRL) contain-
ing 10% FBS and pen-strep. PC-12 cells were maintained
in RPMI 1640 (Cellgro) containing 10% heat-inactivated
horse serum (Gibco BRL), 5% FBS, and pen-strep. To
induce differentiation, PC-12s were plated onto 24-well
plates pre-coated with collagen at a starting density of
20,000 cells/well in maintenance medium overnight, and
then received 50 ng/ml NGF in RPMI 1640 containing
1% heat-inactivated horse serum and pen-strep for the
next 7 days. NGF was replenished every 2 days. CEM
cells were also cultured in RPMI 1640 with 10% FBS and
pen-strep.
Preparation of Campenot cultures
Primary dorsal root ganglion (DRG) neurons from the
superior cervical ganglia of newborn Sprague–Dawley
rats were isolated as described previously (Heerssenet al., 2004). Campenot cultures were established from
some preparations of DRG as described (Campenot,
1977, 1994). Briefly, after isolation, about 105 neurons
were plated in central compartments formed by Teflon
dividers placed across parallel scratches made on 35-mm
dishes. The central compartments contained DMEM, with
pen-strep, and 100 nM AraC supplemented with 10 ng/ml
nerve growth factor (NGF), while the side compartments
contained the same medium supplemented with 100 ng/
ml NGF. This gradient of NGF across the 2 compart-
ments guided the growth of neurites from the central
chambers into the side compartment along the scratches.
On the 6th day of culture, the concentration of NGF in
the central compartment was further reduced to 1 ng/ml.
The cultures were used for experiments on Day 8. Sur-
vival at this stage was estimated at 50% of the original
cells.
Detection of beta-galactosidase
Expression of beta-gal, was assessed by X-gal staining as
described previously (Madry et al., 2003). Briefly, cells were
fixed with 2% formaldehyde and 0.2% gluteraldehyde in
PBS (pH 7.6) at 4 -C for 5 min followed by 3 washes with
PBS. The cells were then incubated with 1 mg/ml X-gal, 1.64
mg/ml potassium ferricyanide, 2.12 mg/ml potassium ferro-
cyanide, and 2 mM magnesium chloride in PBS (pH 7.6) at
37 -C for 12 h.
DNA extraction from tissue and real-time PCR
Male, 5-week-old Balb/C mice were anesthetized by i.p.
injection of 100 mg/kg of ketamine/xylazine (1:1). Approx-
imately 10 Al of standard or mutant AAV vector was
injected in the front half of the tongue. The mice were
allowed free access to food and water after recovering from
anesthesia. At 24 h, 48 h, or 72 h after tongue injection,
mice from each group received an i.p. overdose injection of
pentobarbital. A 20 T 2 mg tissue block was quickly
dissected from the tongue around the injection site, and the
brain stem containing both sides of the hypoglossal nuclei
was collected from each mouse. Samples of cerebral cortex
were collected from other mice as negative controls. DNA
was extracted using the QIAamp DNA Mini Kit (QIAGEN
Inc., Valencia, CA). The copy number of the vector
transgene in each sample was assayed by real-time PCR
using a primer and probe set and cycling conditions
previously described (Lewis et al., 2002).
Construction and packaging of rAAV
The lacZ gene sequence was cloned into an AAV-based
vector plasmid, pACP, which has been described previously
(Cucchiarini et al., 2003).
Mutagenesis of the AAV capsid was carried out using the
ExSite PCR-based Site-directed Mutagenesis Kit (Strata-
J. Xu et al. / Virology 341 (2005) 203–214212gene, La Jolla, CA) and pXX2 (Xiao et al., 1998) as the
template plasmid.Primers used for constructing HN1 were —
Forward 5Vggccgcactttgtacggattcggcttgtcgagacaagcagctaccgca 3V
Reverse 5Vttggcccttaagtgtatagttcataccggtgttgcctctctggaggtt 3V
Primers used for constucting HN2 were —
Forward 5Vaagggacagggacgcactttgtacggattcgggttgtcagcagctaccgcagatgtcaac 3V
Reverse 5Vaagtgtatagttcgatccggtgaggttggtagatacagaacc 3V
Primers used for construction of DMC1 were —
Forward 5Vactcagactactagtgggttgtcagcagctaccgcagatgtcaac 3V
Reverse 5Vcgacttatcttctccggtgaggttggtagatacagaacc 3VIn each primer, bases complementary to the pXX2
template are underlined. In addition to the functional
epitope, each insert included flanking Thr-Gly and Gly-
Leu-Ser residues 5Vand 3Vto the inserts, respectively (Shi et
al., 2001), for flexibility. A unique restriction site was
included in each insert and/or deletion for screening
purposes. All constructs were also verified by sequencing.
Packaging of all rAAV was carried out according to
standard protocols with some modifications (Xiao et al.,
1998). Briefly, vectors were packaged in a 3 plasmid
system by co-complementation of the AAV vector plasmid
with a second plasmid, pXX2, or one of its derivatives,
encoding the AAV-2 replication and encapsidation func-
tions, together with a 3rd plasmid, pXX6, carrying
essential adenoviral helper functions. Purification of the
vector preparations was achieved by a combination of
passage over an iodixanol gradient followed by ion
exchange chromatography using a 1- or 5-ml HiTrap Q
column (Amersham Bioscience, Piscataway, NJ) as pre-
viously described (Zolotukhin et al., 2002). rAAV vector
stocks were titered by real-time PCR using the ABI Prism
7700 Sequence Detection System from Perkin-Elmer
Applied Biosystems (Foster City, CA, USA), as previously
described (Clark et al., 1999). rAAV doses were calculated
based on real-time PCR titers. Functional titers of rAAV
vector preparations after purification were on the order of
1010 per ml. MOI was defined as number of transgenes
rather than virus particles.
Western blotting and immunoprecipitation
293 cells (6–7  106 per 100-mm dish) were transfected
with 10 Ag of each AAV vector plasmid using a standard
calcium phosphate precipitation method. 24 h after trans-
fection, the cells were scraped on ice into phosphate
buffered saline (pH 7.4) containing 1% Igepal CA-630,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1
mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM benzamidine, 1
mM sodium orthovanadate, 1 mM phenylmethylsulphonyl
fluoride, 200 nM staurosporine, and 3.3 U/ml apyrase. The
cell suspensions were homogenized using a 1-ml Wheaton
homogenizer for 10 strokes, and centrifuged at 10,000g, 4
-C for 15 min. Control cell lysate was prepared in the sameway from untransfected cells. The clarified lysates were then
used for immunoprecipitation. The lysates were pre-cleared
with control rabbit antiserum and protein G (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), and then incubated
with a mouse monoclonal antibody against an epitope of the
AAV-2 capsid, A20 (American Research Products, Inc.,
Belmont, MA), together with protein G on a rocker
overnight at 4 -C. The immunocomplexes were then
pelleted by centrifugation at 2,500 rpm for 30 s, washed
with PBS and repelleted 3 times. The pellets were then run
on SDS-PAGE, and immunoblotted with a rabbit polyclonal
antibody against LC8 to check for co-precipitation of this
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